• / Free eNewsletters & Magazine
  • / My Account
Home>China’s Bitter Medicine for Foreign Drug Companies

China’s Bitter Medicine for Foreign Drug Companies

Perspectives Content Submission

Tue, 1 Oct 2013

Published with permission from  Knowledge @ Wharton , Wharton’s online business journal. The Chinese government’s actions against foreign drug makers emerged like a late summer Beijing storm: heavy drops slapping slowly at first, then all at once becoming a disorienting deluge, pounding down in eve

Related Videos

  1. Has China Hit Its Growth Limit?

    China's historical growth drivers have started to plateau, but many untapped industries--particularly in the services sector--are set to take the lead, says Seafarer's Andrew Foster.

  2. Prescribe to Pharma for Emerging -Markets Growth

    Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover.

  3. Reasons to Increase Your Stake in China

    BaoCap's Kevin Carter says there's no imminent landing--hard or soft--in China , and with the country's 35% contribution to global GDP growth, investors should up Chinese exposure in the consumer and tech sectors.

©2017 Morningstar Advisor. All right reserved.